Cerevasc

Cerevasc company information, Employees & Contact Information

Explore related pages

Related company profiles:

CereVasc, Inc. is developing the eShunt System for the treatment of patients with communicating hydrocephalus, one of the most common neurological conditions affecting both children and adults.

Company Details

Employees
33
Address
100 1st Ave,
Industry
Medical Equipment Manufacturing
NAICS
Medical Equipment and Supplies Manufacturing
Surgical and Medical Instrument Manufacturing
Surgical Appliance and Supplies Manufacturing
Dental Equipment and Supplies Manufacturing
Ophthalmic Goods Manufacturing
Dental Laboratories
HQ
Boston, Massachusetts
Looking for a particular Cerevasc employee's phone or email?

Cerevasc Questions

News

CereVasc, Inc. Announces 100th Patient Treated with the eShunt® System - PR Newswire

CereVasc, Inc. Announces 100th Patient Treated with the eShunt® System PR Newswire

A Minimally Invasive Way to Treat Cerebrospinal Fluid Accumulation in the Brain - the-scientist.com

A Minimally Invasive Way to Treat Cerebrospinal Fluid Accumulation in the Brain the-scientist.com

CereVasc, Inc. Announces Results of Groundbreaking Clinical Study of the eShunt® System in the Treatment of Elderly Patients with Normal Pressure Hydrocephalus - Yahoo Finance

CereVasc, Inc. Announces Results of Groundbreaking Clinical Study of the eShunt® System in the Treatment of Elderly Patients with Normal Pressure Hydrocephalus Yahoo Finance

CereVasc Receives Health Canada Investigational Testing Authorization for STRIDE Clinical Trial of the eShunt® System - PR Newswire

CereVasc Receives Health Canada Investigational Testing Authorization for STRIDE Clinical Trial of the eShunt® System PR Newswire

CereVasc, Inc. Receives FDA Breakthrough Device Designation for the eShunt® System for Use in Pediatric Patients - PR Newswire

CereVasc, Inc. Receives FDA Breakthrough Device Designation for the eShunt® System for Use in Pediatric Patients PR Newswire

CereVasc Announces First Patient Randomized to eShunt® System Treatment in STRIDE Pivotal Trial - PR Newswire

CereVasc Announces First Patient Randomized to eShunt® System Treatment in STRIDE Pivotal Trial PR Newswire

CereVasc randomizes first patient in head-to-head study of eShunt, standard of care - MassDevice

CereVasc randomizes first patient in head-to-head study of eShunt, standard of care MassDevice

CereVasc announces 100th patient treated with eShunt System - Med-Tech Insights

CereVasc announces 100th patient treated with eShunt System Med-Tech Insights

CereVasc Appoints Dr. Adel Malek as Chief Medical Officer - citybiz

CereVasc Appoints Dr. Adel Malek as Chief Medical Officer citybiz

Cerevasc gains Health Canada approval for STRIDE trial - NeuroNews International

Cerevasc gains Health Canada approval for STRIDE trial NeuroNews International

CereVasc Announces First Enrollment in STRIDE Clinical Trial of the eShunt® System for Normal Pressure Hydrocephalus - PR Newswire

CereVasc Announces First Enrollment in STRIDE Clinical Trial of the eShunt® System for Normal Pressure Hydrocephalus PR Newswire

CereVasc wins FDA breakthrough designation for eShunt in pediatric patients - MassDevice

CereVasc wins FDA breakthrough designation for eShunt in pediatric patients MassDevice

CereVasc Receives Approval for STRIDE Clinical Trial of the eShunt® System for the Treatment of Elderly Patients with Normal Pressure Hydrocephalus in Argentina - PR Newswire

CereVasc Receives Approval for STRIDE Clinical Trial of the eShunt® System for the Treatment of Elderly Patients with Normal Pressure Hydrocephalus in Argentina PR Newswire

CereVasc Announces Enrollment of the 50th Patient in Pilot Studies of the eShunt® System for Normal Pressure Hydrocephalus - PR Newswire

CereVasc Announces Enrollment of the 50th Patient in Pilot Studies of the eShunt® System for Normal Pressure Hydrocephalus PR Newswire

CereVasc Announces $70 Million Series B Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus - PR Newswire

CereVasc Announces $70 Million Series B Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus PR Newswire

eShunt® System Receives FDA Breakthrough Device Designation - PR Newswire

eShunt® System Receives FDA Breakthrough Device Designation PR Newswire

CereVasc Receives FDA IDE Approval for the STRIDE Pivotal Study of the eShunt System for Treatment of Normal Pressure Hydrocephalus - PR Newswire

CereVasc Receives FDA IDE Approval for the STRIDE Pivotal Study of the eShunt System for Treatment of Normal Pressure Hydrocephalus PR Newswire

CereVasc & LianMedical Announce Corporate Partnership - PR Newswire

CereVasc & LianMedical Announce Corporate Partnership PR Newswire

Tufts Medical Center Neurosurgeons and CereVasc Co-founders Honored by the Society of Vascular and Interventional Neurology for Innovation in Hydrocephalus Treatment - PR Newswire

Tufts Medical Center Neurosurgeons and CereVasc Co-founders Honored by the Society of Vascular and Interventional Neurology for Innovation in Hydrocephalus Treatment PR Newswire

Top Cerevasc Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant